Idéal Investisseur
Français English
CAC 40 :
8 157,82 pts
-0.84%


Last updated : 24/04/2026 - 17h35
🏠 Home   ➤    Stock news

Eurofins Divests MET Labs Division to UL Solutions for 575 Million Euros

Eurofins Scientific has announced the signing of an agreement to divest its Electrical & Electronic Testing division (MET Labs) to UL Solutions Inc. for an enterprise value of 575 million euros. This divestiture marks a strategic turning point for the group, refocusing on its core life testing activities.


Eurofins Divests MET Labs Division to UL Solutions for 575 Million Euros

Overview of MET Labs

MET Labs, the divested business, is an international network of laboratories specializing in product safety testing, inspection, and certification for the consumer electronics, automotive, telecommunications, and industrial sectors. The division employs about 1,300 staff worldwide and is expected to generate more than 180 million euros in revenue by 2026, with profitability largely in line with the group's average.

Strategic Refocus and Use of Proceeds

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
Before 9 AM every morning Euronext data AI-powered analysis

Eurofins states that this divestiture is part of its strategy to refocus on its core life testing activities. The group plans to allocate the proceeds from this sale to several priorities: debt reduction, capital expenditures for owned laboratories and sites, development of next-generation digital solutions, robotics and artificial intelligence, share buybacks, and strategic acquisitions to strengthen its leadership positions in the markets for food, environmental, pharmaceutical, clinical, and related testing.

Transaction Completion Pending Regulatory Approvals

The completion of the transaction remains subject to customary regulatory approvals and is expected before the end of the year 2026. The press release does not specify any potential specific financial or operational impacts related to the divestiture, nor the detailed conditions of the transition.



Sector Santé · Pharmacie Services médicaux


Assurance vie

Context

Period
  • Period: 2025
Key reported figures
  • Revenue: 7 296 M€
  • Revenue growth: 5,0%
  • EBITDA: 1 561 M€
  • EBITDA margin: 21,4%
  • Net income: 473 M€
  • Free cash flow: 876 M€
  • Net debt: 3 641 M€
  • Dividend per share: 0,72 €
Guidance from the release
  • Nous sommes satisfaits d’avoir atteint nos objectifs 2025 et de démontrer la solidité du portfolio Eurofins.
  • La performance 2025 est soutenue par la croissance organique et l’expansion des marges, avec un flux de trésorerie libre robuste et un endettement maîtrisé.

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
Avant 9h00 1000+ inscrits 100% gratuit